Member Info for AquaeSulis01

The percentage increase is calulated using the following formula; 77000 - 22000 / 22000* 100

The percentage increase is actually 250% but fairly irrelevant as between the US, UK, Italy and France there are estimated to be over 10M psoriasis sufferers and yet the number of regular subscribers for axisbiotix is circa 400 so along way to go but does illustrate the potential if we get a decent partner to market it.

Wrong about share dilution being the only way to fund drilling then Roger, although realised less than half the expected value of the original ditau sale value "Power Metal now moves to become a strategic investor in Kavango with an 9.85% holding on Admission next week, carrying a value of some £1.25m at yesterday's closing market mid-price."

Still a good deal in the present climate, just need to actually find a commercial strike with the next drilling campaign

With you on that Toyin, just managing Clio's expectations

So what do you think the sp will rise to if a small well capitalised pharma company with a lowly M/C of £34M signed a blockbuster deal for such an exciting product with a Major Pharma then moniman?

Thanks Toyin, what of course we no longer know is whether it includes European sales but the figures show that Between 29/10/21 and 24/11/22 there were 2830 orders, whilst Between 17/10/22 and 20/11/23 there were 4551 orders so an improvement from a low base with minimal advertising but nothing to get too excited about, we need that multi-national partnership to market it for us

Theanalyzer, what you describe is a 3rd quarter update which many companies provide but Opti isn't one of them. The issue is that in the opening paragraph the purpose of the RNS was given as providing progress against achieving profitability at Business Unit level, but failed to inform whether any were at least on a monthly basis were currently profitable or not, so what was the point of the RNS? Indeed the reference to profitability by end 2023 had been dropped altogether; a reminder of what was stated at the EOY RNS "Stephen O'Hara, CEO of OptiBiotix, commented: "The focus for 2023 has been on moving the business to profitability by a reduction in costs, a focus on existing partners returning to forecast, bringing in new partners particularly in the USA and Asia, and expanding e-commerce channels to reduce partner dependency. Good progress has been made in each of these areas. This is all part of plans for each business unit (USA, India, Ecommerce, B2B) to reach profitability, at least on a monthly basis by the end of the calendar year."

Well Jason, perhaps you would now care to explain exactly what the "bent Institutional Investors" knew that wasn't in the half year forecast?

Gum not him

A toothpaste that tackles him disease does under medical as would a medical shampoo

So we agree that renaming the pillars and associated subsidiary to reflect the healthcare area they are focused on I.e. Food Supplements and Cosmetics would end any confusion

NickE, first of all thanks for sharing the guts of the response. Regarding the Pillars, I struggle to see how they could be divested in the manner described as they currently are a combination of product groups (skinbiotix which is the Lactobacillus Rhamnosis lysate, and Axisbiotix currently probiotic mixes for psoriasis and soon to be joined by acne probiotic mixes) and Healthcare Sectors the product groups are targeted at. For consistency the first two pillars ought to be called Foodsupbiotix and Cosmetbiotix.

just a reminder from the EOY results RNS that medibiotix and cleanbiotix are both based on the additional properties of skinbiotix whilst pharmabiotix will just be the products clinically proven and regulatorily approved to a point where they can be prescribed

"MediBiotix Pillar (MedTech applications e.g. woundcare)

The MediBiotix Pillar is focusing on applying SkinBiotix technology in medical device applications, looking at targeting eczema in the first instance. The aim would be to alleviate eczema symptoms using the gut-skin axis in the same way that AxisBiotix acts to alleviate symptoms in psoriasis. This development route is still being explored by management.

Other areas for application include various classes of skin wounds. Due to the complexity but significant opportunity of the woundcare area, Management believes a joint development agreement with an industry partner is the best way forward. Early discussions with potential global partners in the medtech sector have commenced.

CleanBiotix Pillar (anti-infection)

With the impact of the pandemic coupled with the increasing incidence of healthcare acquired infections, such as MRSA, preventing infection is of paramount concern to healthcare practitioners. From early studies of SkinBiotix, there is data demonstrating its effectiveness in preventing the most common skin pathogen, Staphylococcus aureus (SA), from sticking to and growing on skin surfaces. The potential for SkinBiotix technology in this area is exciting, but is also challenging, therefore, this would be another area where outlicensing the programme would be the obvious option."

So in summary, if someone bought the Skinbiotix pillar surely there would be no Medibiotix or Cleanbiotix as things stand?

Bearing in mind the opening paragraph "The Company's focus for 2023 has been on achieving profitability on a per business unit basis and, once achieved ultimately resulting in overall profitability. This is being driven by a reduction in costs, a focus on existing partners returning to forecast, bringing in new partners particularly in the USA and Asia, and building an e-commerce business through multiple channels to reduce partner dependency. This update seeks to capture the progress made with first generation products since the restructuring of the management team in March in each of these areas. An update on second generation products will be provided separately in due course."

Bearing in mind the increase in marketing spend, can anyone tell me from the information provided in the rest of the update whether profitability for any or all the individual business units has been achieved or not?

Clio, buys and sells are often misclassified and who's to say that SOH hasn't released a number of shares for the MM to drip feed into the market again

Turtle, the expectation is that the company will make an accretive acquisition either before or just after Christmas. If that does go ahead as plan then funds will be needed, but that wont necessary see the share price fall, indeed it may well increase. A reminder of what was said during last years placing when the acquisition was first spoken of "The Company's strategy also involves the evaluation of other opportunities that would provide synergies and accelerated routes to market. The Company is in ongoing discussions to acquire a private company that provides a variety of branded topical products for common dermatological conditions such as psoriasis and eczema to NHS hospitals, dispensing practices and retail pharmacies. The proposed target is profitable and the Company sees a number of synergies to improve this. However, there is no certainty of timing or execution as the Company would need to agree additional funding using debt and/or equity and any acquisition would be conditional on satisfactory diligence."

Hope that helps

Thanks for posting mol. Might be worth posting on the Opti board too as elements appear to relate to the function micobiome modulators are designed to perform I would suggest?

Roughly £2M of the £2.6M raised post last years accounts appears to have been spent but I would guess all required cash for next 12 months would be swept up in the debt/equity required to conclude the anticipated near term acquisition

Happy to report that SA has clarified with TW that the reason for the additional extension from 3-4mths to 12mths was to (in my own words) safeguard against any unanticipated but not expected delays to commercialisation, so I'm feeling a lot happier this morning :)

Yes indeed martinu so need to only promise timelines within your gift to deliver. Perhaps you will appreciate SOH's negotiating skills a little bit more as well, after all he negotiated milestone payments from the big boys on top of scale-up costs

No opinions from either you or I affect the share place, my posting arrived after the sp fell to its current level not before. As you state, hopefully Stuart will provide some clarity over why the additional extension from 4 - 12 mths is now necessary and yet was not apparent back in May; indeed we were led by comments by Stuart to TW/Elric that the trials had been brought forward with the speculation that the VIP's were keen to go to market.